Lab
Sentara Reference Lab Solutions, LLC
Sentara Reference Lab Solutions, LLC was paid $1.84M by Medicaid between Oct 2021 and Nov 2024, across 148 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 8.6% of everything it billed.
33Billing provider infoSENTARA REFERENCE LAB SOLUTIONS, LLC
NORFOLK, VA 23507
NORFOLK, VA 23507
33aNPI1396357901assigned 08/17/2020
33bProvider typeClinical Medical Laboratory
28Total paid$1.84M
24GClaims164,392
24DCodes billed148
24AFirst – last monthOct 2021 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#15 of 78
Median peer was paid$37K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 31,353 | $366K | |
| 2022 | 51,412 | $653K | |
| 2023 | 34,239 | $374K | |
| 2024incomplete | 47,388 | $442K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 8.6% | 2,627 | 2,521 | $159K |
| 80061 | Lipid panel | 6.7% | 11,922 | 11,507 | $123K |
| 80053 | Comprehensive metabolic panel | 5.7% | 13,937 | 12,741 | $104K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.7% | 5,386 | 5,165 | $104K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.3% | 3,332 | 3,171 | $97K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.1% | 3,335 | 3,176 | $93K |
| 80050 | General health panel | 4.4% | 5,808 | 5,654 | $81K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.3% | 10,832 | 10,395 | $79K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.8% | 2,502 | 2,381 | $70K |
| 87481 | 3.7% | 1,278 | 1,210 | $69K | |
| 84443 | Thyroid stimulating hormone (TSH) | 3.7% | 6,477 | 6,202 | $69K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 1,342 | 1,011 | $68K |
136 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 9,076 | $47K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.1% | 1,294 | $39K |
| G0475 | Hiv antigen/antibody, combination assay, screening | 1.9% | 2,148 | $35K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.7% | 1,120 | $32K |
| 84439 | 1.7% | 4,418 | $31K | |
| 82607 | 1.6% | 2,556 | $30K | |
| 86003 | 1.6% | 503 | $29K | |
| 82728 | 1.5% | 2,646 | $28K | |
| 85027 | 1.3% | 5,066 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 3,933 | $24K |
| 86803 | 1.2% | 2,045 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 3,679 | $22K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,137 | $18K |
| 83550 | <1% | 2,515 | $17K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,096 | $16K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 755 | $16K |
| 83540 | <1% | 2,648 | $13K | |
| 87536 | <1% | 189 | $12K | |
| 82746 | <1% | 1,043 | $12K | |
| 86780 | <1% | 1,110 | $11K | |
| 83880 | <1% | 382 | $10K | |
| 86235 | <1% | 149 | $10K | |
| 87081 | <1% | 1,768 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,569 | $10K |
| 87077 | <1% | 1,455 | $9K | |
| 82043 | <1% | 2,615 | $8K | |
| 87186 | <1% | 1,211 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 156 | $7K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 374 | $7K |
| 83735 | <1% | 1,735 | $7K | |
| 86140 | <1% | 1,809 | $7K | |
| 83970 | <1% | 263 | $7K | |
| 80076 | <1% | 984 | $6K | |
| 84403 | <1% | 371 | $6K | |
| 82784 | <1% | 506 | $6K | |
| 82785 | <1% | 453 | $6K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 13 | $6K |
| 87340 | <1% | 632 | $5K | |
| 81001 | <1% | 1,918 | $4K | |
| 86038 | <1% | 457 | $4K | |
| 87150 | <1% | 217 | $4K | |
| 85652 | <1% | 1,887 | $4K | |
| 86361 | <1% | 164 | $4K | |
| 86364 | <1% | 210 | $4K | |
| 85610 | <1% | 897 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 117 | $3K |
| 84146 | <1% | 193 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 84 | $3K |
| 87070 | <1% | 443 | $3K | |
| 86225 | <1% | 252 | $3K | |
| 80074 | <1% | 66 | $3K | |
| 84481 | <1% | 228 | $2K | |
| 83001 | <1% | 142 | $2K | |
| 86258 | <1% | 103 | $2K | |
| 83655 | <1% | 189 | $2K | |
| 86160 | <1% | 130 | $2K | |
| 82533 | <1% | 134 | $2K | |
| 84702 | <1% | 230 | $2K | |
| 83516 | <1% | 83 | $2K | |
| 86334 | <1% | 111 | $2K | |
| 87205 | <1% | 466 | $2K | |
| 84402 | <1% | 111 | $2K | |
| 83690 | <1% | 295 | $2K | |
| 82024 | <1% | 115 | $2K | |
| 86431 | <1% | 403 | $2K | |
| 83721 | <1% | 180 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 35 | $1K |
| 82378 | <1% | 97 | $1K | |
| 82105 | <1% | 103 | $1K | |
| 86706 | <1% | 191 | $1K | |
| 83615 | <1% | 260 | $1K | |
| 84480 | <1% | 107 | $1K | |
| 80164 | <1% | 105 | $1K | |
| 84550 | <1% | 349 | $1K | |
| 84153 | <1% | 76 | $1K | |
| 80069 | <1% | 195 | $1K | |
| 82570 | <1% | 282 | $1K | |
| 85046 | <1% | 226 | $983.83 | |
| 86376 | <1% | 85 | $977.70 | |
| 84100 | <1% | 435 | $898.56 | |
| 84165 | <1% | 68 | $833.06 | |
| 82565 | <1% | 195 | $773.12 | |
| 80197 | <1% | 67 | $755.15 | |
| 84460 | <1% | 189 | $743.06 | |
| 86300 | <1% | 130 | $720.00 | |
| 86800 | <1% | 54 | $692.03 | |
| 83883 | <1% | 77 | $671.50 | |
| 82550 | <1% | 112 | $588.53 | |
| 86850 | <1% | 258 | $563.25 | |
| 86008 | <1% | 40 | $559.44 | |
| 86762 | <1% | 84 | $548.32 | |
| 86618 | <1% | 43 | $523.93 | |
| 83002 | <1% | 29 | $518.56 | |
| 84156 | <1% | 193 | $500.40 | |
| 83010 | <1% | 44 | $478.04 | |
| 83921 | <1% | 27 | $475.50 | |
| 84450 | <1% | 191 | $456.82 | |
| 84436 | <1% | 83 | $453.42 | |
| 86704 | <1% | 49 | $433.44 | |
| 80373 | <1% | 44 | $430.43 | |
| 86900 | <1% | 221 | $367.61 | |
| 86901 | <1% | 221 | $367.61 | |
| 80177 | <1% | 42 | $365.67 | |
| 83520 | <1% | 25 | $347.10 | |
| 86039 | <1% | 45 | $345.96 | |
| 85730 | <1% | 74 | $336.56 | |
| 81003 | <1% | 185 | $318.60 | |
| 82950 | <1% | 138 | $298.54 | |
| 86200 | <1% | 28 | $297.85 | |
| 87102 | <1% | 50 | $296.12 | |
| 83525 | <1% | 39 | $287.94 | |
| 82465 | <1% | 86 | $278.40 | |
| 83020 | <1% | 26 | $253.00 | |
| 86705 | <1% | 79 | $235.40 | |
| 84681 | <1% | 13 | $231.40 | |
| 82150 | <1% | 43 | $213.84 | |
| 86696 | <1% | 12 | $212.85 | |
| 84425 | <1% | 31 | $188.40 | |
| 82172 | <1% | 13 | $181.85 | |
| 82977 | <1% | 30 | $172.80 | |
| 86480 | <1% | 61 | $159.14 | |
| 86592 | <1% | 44 | $143.68 | |
| 84478 | <1% | 30 | $143.47 | |
| 86787 | <1% | 16 | $138.00 | |
| 87899 | <1% | 12 | $121.99 | |
| 82947 | <1% | 29 | $106.11 | |
| 87427 | <1% | 12 | $105.38 | |
| 83718 | <1% | 18 | $98.28 | |
| 83521 | <1% | 18 | $85.80 | |
| 85018 | <1% | 39 | $74.94 | |
| 85014 | <1% | 39 | $70.20 | |
| 85379 | <1% | 27 | $70.20 | |
| 82248 | <1% | 14 | $65.26 | |
| 84520 | <1% | 19 | $51.35 | |
| 86593 | <1% | 12 | $48.40 | |
| 86709 | <1% | 53 | $33.78 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROERMANN, ROBERT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Virginia Beach, VA | $480K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.